Studies also showed that genetic polymorphisms affecting adropin levels were associated with dyslipidemia and cardiovascular risks, further emphasizing the hormone’s role in metabolic and cardiovascular health in kidney disease patients [123,124,125]. Here, ENHO is linked to metabolic syndrome.